References
- Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360(9335): 752–60
- Dickstein K. ELITE II and Val-HeFT are different trials: Together what do they tell us? Curr Control Trials Cardiovasc Med 2001; 2(5): 240–3
- Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT—the emergence of new treatment options. J Clin Hypertens (Greenwich) 2002; 4(1): 52–7
- Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995–1003
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253–9
- Garg J, Bakris GL. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep 2002; 4(3): 185–90
- Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor—associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000; 160(5): 685–93
- Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289(19): 2560–71
- Summary of revisions for the 2003 clinical practice recommendations. Diabetes Care 2003; 26(1 Suppl): S3